New drug cocktail aims to fight tough childhood cancer
NCT ID NCT07318831
First seen Jan 10, 2026 · Last updated Jun 23, 2026 · Updated 18 times
Summary
This phase II trial tests a combination of four drugs—chidamide, dinutuximab beta, irinotecan, and temozolomide—in 27 children whose neuroblastoma has returned or not responded to standard treatment. The goal is to see how well the regimen controls the cancer and to monitor side effects closely. The study is currently recruiting participants.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for NEUROBLASTOMA (NB) are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Tianjin Medical University Cancer Institute & Hospital
RECRUITINGTianjin, Tianjin Municipality, 300060, China
Contact Phone: •••-•••-•••• Email: •••••@•••••
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
Chidamide, Dinutuximab Beta, Irinotecan, and Temozolomide
What this could lead to
If this works, it could offer a new treatment option for children with hard-to-treat neuroblastoma, potentially improving cancer control and survival.
What could go wrong
This is a small, early-phase trial with only 27 participants, so results may not apply to all children. The drug combination may cause significant side effects, and it is not a cure.
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.